Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment.

Autor: Sosa Cuevas E; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Mouret S; Dermatology, Allergology & Photobiology Department, CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France., Vayssière G; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Kerboua S; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Girard P; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Molens JP; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Manceau M; Department of Medicine, Clinical Investigation Center, CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France., Charles J; Dermatology, Allergology & Photobiology Department, CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France., Saas P; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France., Aspord C; Institute for Advanced Biosciences, Team: Epigenetics, Immunity, Metabolism, Cell Signaling & Cancer, Inserm U 1209, CNRS UMR, Université Grenoble Alpes, Grenoble, France.; R&D Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Dec 02; Vol. 15, pp. 1507938. Date of Electronic Publication: 2024 Dec 02 (Print Publication: 2024).

Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells.

Autor: Lenogue K; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38700 La Tronche, France.; PDC*line Pharma, 38701 Grenoble, France.; Research and Development laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, 38701 Grenoble, France., Walencik A; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38700 La Tronche, France.; HLA Laboratory, Etablissement Français du Sang Centre-Pays de la Loire, 44011 Nantes, France., Laulagnier K; PDC*line Pharma, 38701 Grenoble, France., Molens JP; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38700 La Tronche, France.; Research and Development laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, 38701 Grenoble, France., Benlalam H; CRCINA, INSERM, Université d'Angers, Université de Nantes, 44011 Nantes, France., Dreno B; Onco-Dermatology Department, CHU Nantes, CIC 1413, CRCINA, Université de Nantes, 44093 Nantes, France., Coulie P; De Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium., Pule M; Cancer Institute, University College London, London WC1E 6BT, UK., Chaperot L; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38700 La Tronche, France.; Research and Development laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, 38701 Grenoble, France., Plumas J; Immunobiology and Immunotherapy of Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38700 La Tronche, France.; PDC*line Pharma, 38701 Grenoble, France.; Research and Development laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, 38701 Grenoble, France.; Cancer Institute, University College London, London WC1E 6BT, UK.

Publikováno v: Vaccines [Vaccines (Basel)] 2021 Feb 10; Vol. 9 (2). Date of Electronic Publication: 2021 Feb 10.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.